Summary of studies included in these analyses
| Name of study . | Country . | Year . | Age range . | n* . | Measures available . |
|---|---|---|---|---|---|
| ARIC (10) | U.S. | 1993–1995 (visit 3) | 49–73 | 10,873 | FPG |
| AusDiab (5) | Australia | 1999–2000 | 25–90 | 2,052 | FPG, 2-h PG, A1C |
| BMES (11) | Australia | 1992–1994 | 45–97 | 2,915 | FPG |
| CURES (12) | India | 2002–2004 (phase III) | 20–85 | 2,200 | FPG, 2-h PG, A1C |
| Hiroshima study (4) | Japan | 1990–2004 | 17–99 | 12,873 | FPG, 2-h PG, A1C |
| MESA (14) | U.S. | 2002–2004 (second examination) | 45–85 | 5,920 | FPG, A1C |
| NHANES III (15) | U.S. | 1988–1994 | 40–74 | 2,869 | FPG, 2-h PG, A1C |
| Pima Indian study (17) | U.S. | 1982 (first examination) | 15–85 | 1,829 | FPG, 2-h PG |
| SiMES (18) | Singapore | 2004 | 40–79 | 3,170 | A1C |
| Name of study . | Country . | Year . | Age range . | n* . | Measures available . |
|---|---|---|---|---|---|
| ARIC (10) | U.S. | 1993–1995 (visit 3) | 49–73 | 10,873 | FPG |
| AusDiab (5) | Australia | 1999–2000 | 25–90 | 2,052 | FPG, 2-h PG, A1C |
| BMES (11) | Australia | 1992–1994 | 45–97 | 2,915 | FPG |
| CURES (12) | India | 2002–2004 (phase III) | 20–85 | 2,200 | FPG, 2-h PG, A1C |
| Hiroshima study (4) | Japan | 1990–2004 | 17–99 | 12,873 | FPG, 2-h PG, A1C |
| MESA (14) | U.S. | 2002–2004 (second examination) | 45–85 | 5,920 | FPG, A1C |
| NHANES III (15) | U.S. | 1988–1994 | 40–74 | 2,869 | FPG, 2-h PG, A1C |
| Pima Indian study (17) | U.S. | 1982 (first examination) | 15–85 | 1,829 | FPG, 2-h PG |
| SiMES (18) | Singapore | 2004 | 40–79 | 3,170 | A1C |
*Number of participants aged 20–79 years included in the analysis.